Key Takeaways
- Strong quarter, margin spike not the new normal: EBITDA hit 28%, but management explicitly called it unsustainable, driven by seasonal respiratory mix and phasing; gross margin rose 166 bps YoY to 68%.
- US supply disruptions mask underlying momentum: Lamivudine supply issues depressed revenue, while Albuterol share rebuilt to 21%+ and Lanreotide supply normalization by March sets up a Q1 ramp.
- The pipeline is graduating from marginal to step-function growth: Generic Advair filing commenced, Abraxane launch targeted for H2 FY26, and three sizable respiratory assets are expected in the US over the next 15–18 months.
- India investment cycle is deliberate, not accidental: The 1,800+ field force additions since FY23 and 500+ retail task force hires are margin reinvestment into branded prescription and trade generics growth, funded by productivity gains.
- What to watch next quarter: Lanreotide supply ramp execution, Abraxane approval timing and PAI clarity, the Virgonagar facility classification, and whether FY26 revenue guidance firms up with the budget.
US Business: Supply Fixes and Pipeline Inflection
- Lamivudine disruption: Q3 US revenue of $226 mn was weighed down by a supply disruption in Lamivudine; adjusted for that, revenue would have been on a growth trajectory.
- Albuterol share rebuild: Market share recovered from the post-Indore-inspection dip to 21%+; further gains are expected to be moderate given supply dependence and the high-volume base.
- Lanreotide normalization: Supply is currently at 50–60% of capacity across two partner manufacturing lines; full capacity is expected by end of March, enabling a Q1 ramp and inventory build.
- Pricing stability: No abnormal price trajectory observed in the US; pricing differs by channel (retail, institution, government) but nothing unusual, and Albuterol pricing is stable other than marginal erosion.
- Revlimid: Sequentially flat QoQ; FY26 sales pattern will differ from FY25 as more competitors enter the market.
Vohra: "the last three years we have now been setting up facilities in the US. So, there will come a time when we begin to understand the economics of shipping straight from India and having potential duties or whatever and the freight with it, linking up with what the cost of manufacturing and supplying from the US is. So, in some ways our model is derisked to a large extent for our portfolio"
Pipeline: The Step-Function Shift
- Generic Advair: Filing of this major inhalation asset has commenced; launch planned in late H1 FY26 from the US facility, with derisking progressing as expected.
- Abraxane: Launch expected toward the back end of H2 FY26 from the Goa facility, post-approval; timing depends on approval date, with management estimating 6–9 months from whenever approval arrives.
- Abraxane PAI uncertainty: Management is not clear whether a pre-approval inspection is required; the belief is that if one is needed, it will follow shortly since the site has exited OAI status.
- Respiratory pipeline depth: Three more sizable respiratory assets are expected to launch in the US over the next 15–18 months; management framed the trajectory as step-function increases, not marginal ones, with each approval materially lifting the portfolio.
- Peptide launches: Two planned in FY26, with approximately three over the next 15 months.
- Symbicort: Site transfer completed; approval expected within 18 months, targeting a second-half FY27 launch.
- QVAR: Indore will be the site for approval.
- Oligonucleotides: Filing of some products expected in a three-to-five-year timeframe.
Vohra: "if your question is whether this will double, triple, it's going to be moving up step functions, it's not going to be moving marginal increases with each asset being approved."
India Business: Investing Margin Gains into Growth
- Branded prescriptions: Healthy 10% YoY growth despite seasonal headwinds in the acute category; branded prescriptions are outpacing market growth in respiratory, urology and acute.
- Trade generics: Back on a growth trajectory, supported by distribution execution, new introductions and technological interventions; previous year benefited from a 3–4% price increase versus only ~1% this year, with the 2–3% gap offset by overall market growth.
- Volume growth: India volume growth was around 2%, with the balance from price and new introductions; management expects some improvement in volume growth in coming years.
- Field force investment: 1,800+ reps added from FY23 through 9M FY25 in branded prescription, plus 500+ in the retail task force; these costs are funded by productivity gains from automation and improved rep detailing, not price increases.
- Profitability: India business profitability improved largely through productivity optimization; management reinvested margin gains into more reps and declined to provide margin-specific guidance.
- Consumer health: Strong traction with anchor brands Nicotex, Omnigel, Cipladine maintaining #1 leadership; operating profitability is consistent.
- Consumer wellness growth: Driven by a base effect (two large assets transferred to consumer health in Q1 last year caused distribution disruption), plus faster growth from branding efforts, one acquisition, and one or two BD deals.
- Semaglutide positioning: Cipla aims to be in the first wave of launches in India when the market forms in 2026; also available to support Lilly if chosen as a partner.
International Markets: South Africa and EMEU Deliver
- South Africa: 21% growth in ZAR terms, rock solid; private market ranks #2, prescription business maintains #1 position; growth driven by new launches taking share and being selective about tender business to maintain margins.
- EMEU: 20% YoY growth in USD with an uptick in both TTM and B2B categories; operating margins sustained.
- South Africa margin focus: Management's stated priority is margin expansion in this market.
- ARV exposure: Antiretroviral agents (API and FDF combined) are estimated at not more than 3–5% of overall revenues, with margins significantly lower than the company average.
Quality and Facilities: Clearing the Overhang
- Goa facility: Cleared by US FDA with VAI classification.
- Virgonagar, Bengaluru: Inspected by USFDA; eight 483 observations issued; official classification is awaited.
- Medispray facility: Inspected by USFDA; one 483 observation issued; official classification is awaited.
- US manufacturing footprint: DPI, MDI and large-volume OSD facilities are now operational in the US; filings from these facilities have commenced, derisking the MDI, DPI and OSD portfolios against potential tariffs.
- InvaGen facility: Launch timelines are building in an FDA inspection.
Vohra: "quality is a function of practice equipment and talent. And we have worked on all three of them."
Margins: The 28% Print and Why It Will Not Repeat
- Gross margin: 68%, up 166 bps YoY, driven by overall mix change.
- Q3 EBITDA at 28%: Management explicitly stated this is not sustainable; it reflects favorable mix (respiratory uptick in Q3 is always the best quarter) and some phasing impact of costs, with Q4 being seasonally low.
- R&D spend: ₹360 cr (~5% of revenue), driven by product filing costs and developmental efforts; guidance of 5–6% of revenue retained to add more product programs, though clinical trial requirements may relax.
- Employee costs: Include strategic investments in the India field force and onboarding of marketing agent employees due to a trade generics model change, offset by future commission reduction.
- FY26 margin guidance: Will be provided once the budget is finalized.
Adukia: "No, I don't think Cipla can do 28% EBITDA margins... 28% is not a sustainable margin for us. That's what I meant."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue growth | Retain guidance to grow top line | FY26 |
| Generic Advair launch | Launch from US facility | Late H1 FY26 |
| Generic Abraxane launch | Launch from Goa facility post-approval; 6–9 months from approval date | Back end of H2 FY26 |
| Lanreotide supply normalization | Full capacity from partner; ramp-up and inventory build | End of March (Q4), ramp in Q1 |
| Lanreotide capacity expansion | 20–25% higher than index level of 100; also examining alternate sites | Post-April |
| Peptide launches | Two launches | FY26 |
| Three sizable US respiratory assets | Launch in the US | Next 15–18 months |
| Symbicort launch | Site transfer done; approval and launch | H2 FY27 |
| R&D spend | 5–6% of revenue | Ongoing |
| EBITDA margin guidance | To be provided once budget is finalized | FY26 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹7,073 cr, +8% YoY |
| EBITDA margin | 28%, up 184 bps YoY and 138 bps QoQ; not sustainable at this level |
| Gross margin after material cost | 68%, 166 bps above last year |
| Profit after tax | ₹1,571 cr, ~22% of sales |
| Effective tax rate | 25.5%, adjusted for one-offs; full-year guidance 27%–28% |
| R&D investment | ₹360 cr, ~5% of revenue; FY25 guidance retained at 5%–6% |
| Total expenses | ₹2,820 cr, in line with revenue growth |
| Net cash equivalent | ~₹8,947 cr, as of 31st Dec 2024; debt including lease liability at ₹466 cr |
| ROIC | 30% |
| North America quarterly revenue | $226 million |
| One India revenue growth | +10% YoY |
| One Africa revenue growth | +9% YoY in USD terms; South Africa +21% in ZAR terms |
| EMEU revenue growth | +20% YoY in USD terms |
| Albuterol market share | 21%, as per IQVIA MAT week ended 27th Dec 2024; slightly ahead recently |
| Chronic mix | 61.5%, as per MAT IQVIA December '24 |
| Brands with revenue >₹100 cr in IPM | 26, five added during the quarter |
| India volume growth | ~2%, balance from price and new introductions |
| Price erosion in US base portfolio | High single digit on an overall basis |
| Lanreotide supply level | 40%–50% of partner's full capacity index; expected back to 100 by end of March |
| US respiratory portfolio annual run-rate | Slightly more than $150–$200 million |
| Consumer wellness India quarterly run-rate | ~₹380 cr, up from ~₹250 cr per quarter last year |
| Field force additions (India branded Rx) | 1,800+ feet on ground added from FY23 to 9M FY25 |
| Trade generics retail task force | 500+ feet on ground added |
| PEPFAR exposure | Less than ₹0.1 cr, less than 0.2% of Cipla's business |
| FY25 EBITDA guidance | Trending higher than 24.5%–25.5% earlier range |
| Dividend payout guidance | ~30% |
| Symbicort US approval timeline | Within 18 months, second-half FY27 launch |
| Generic Advair launch timeline | Late H1 FY26 |
| Generic Abraxane launch timeline | Back end of H2 FY26, post-approval |